Fact: AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on research, development, and potential commercialization of mental health treatments, primarily in the US, Germany, and Canada. Its pipeline includes BPL-003 (intranasal mebufotenin benzoate for treatment-resistant depression (TRD) and alcohol use disorder in Phase 2a/2b), RL-007 (pro-cognitive neuromodulator for schizophrenia-related cognitive impairment in Phase 2b), ELE-101 (serotonergic psychedelic for major depressive disorder), VLS-01 (DMT transmucosal film for TRD in Phase 2), EMP-01 (R-MDMA for social anxiety disorder in Phase 2), non-hallucinogenic 5-HT2A agonists (EGX-A/B for TRD), plus COMP360 (psilocybin) and GRX-917.[Yahoo Finance Profile]
Fact: The company was founded in 2018 as atai Life Sciences N.V., went public in 2021, merged with Beckley Psytech (founded 2019) in 2025, redomiciled to Delaware (US) and renamed AtaiBeckley Inc. in December 2025, with headquarters in New York, NY. It has approximately 99-117 full-time employees and a fiscal year ending December 31.[Wikipedia] [Company Site]
Interpretation: The merger positioned AtaiBeckley as a leader in psychedelic mental health therapies by combining pipelines and expertise.
Uncertainty: Long-term success depends on clinical trial outcomes, regulatory approvals (e.g., FDA), and commercialization, none of which are guaranteed.
Fact (Historical Returns, as of ~July 16, 2026 data):
| Period | ATAI Return | S&P 500 Return |
|---|---|---|
| YTD | 74.82% | 10.05% |
| 1-Year | 164.81% | 20.28% |
| 3-Year | 253.96% | 67.22% |
| 5-Year | 58.86% | 74.10% |
Annual performance highlights (approximate, adjusted): Strong recovery in 2025 (~207% in one reported period) following weaker years (e.g., -65% in 2022, -47% in 2023).[Yahoo Finance Historical Data] [Macrotrends]
Interpretation: The stock has shown significant volatility typical of clinical-stage biotechs, with outsized gains in 2025-2026 likely driven by clinical progress and sector interest.
Uncertainty: Future performance is highly sensitive to news flow on trials, partnerships, or M&A; past returns do not predict future results.
More information: Yahoo Finance Historical Prices | MarketWatch Performance
Fact: As a pre-commercial clinical-stage company, revenue is minimal (TTM ~$3.49M; examples include $1.555M in Q1 2025, ~$4.1M FY2025 in some reports). Net losses are substantial (TTM net income attributable ~-$663M, quarterly examples ~-$26M; annual figures can include one-time items post-merger).[Yahoo Finance Financials]
| Metric (approximate, various periods) | Value | Notes |
|---|---|---|
| Cash & Equivalents / Short-term Securities | $108M (Mar 2025); up to ~$231M (later mrq); runway into 2027+ | Supported by equity financings; projections assume continued operations |
| Total Assets | $159M - $293M (recent annual/quarterly) | Primarily cash and investments |
| Total Equity | ~$117M - $222M | Positive but impacted by losses |
| EPS (TTM) | -$2.84 | Diluted |
| Operating Expenses (quarterly examples) | $21M - $24M | R&D and G&A heavy |
Fact: Company expects cash, securities, and holdings sufficient to fund operations into 2027 (or later per some updates), with no dividends.[IR Site]
Interpretation: High burn rate is standard for biotech R&D; recent financings and potential M&A provide runway but dilute shareholders.
Uncertainty: Actual cash burn and runway depend on trial costs, partnership revenues, and any acquisition outcomes; large reported annual losses may include non-recurring merger-related items.
More information: Yahoo Balance Sheet | Yahoo Income Statement | Company IR Releases
Fact: Consensus rating is Strong Buy/Buy from ~12-13 analysts, with average 12-month price target ~$14.00-$16.17 (range: low ~$7.00, high $25.00).[Zacks] [Benzinga]
| Analyst / Firm | Rating | Price Target | Date (approx.) |
|---|---|---|---|
| HC Wainwright | Buy | $25.00 | June 2026 |
| Canaccord Genuity | Buy (raised) | $17.00 (from $15) | July 2026 |
| Jefferies | Hold (downgraded) | $7.50 (from $10) | July 17, 2026 |
| Jones Trading | Hold (downgraded) | -- | July 17, 2026 |
| Consensus (multiple) | Strong Buy | ~$14.17 average | Recent |
Interpretation: Overall bullish sentiment reflects pipeline potential and sector tailwinds, though recent downgrades signal caution on valuation post-rally.
Uncertainty: Ratings and targets are opinions that can change quickly with new data or market conditions; not investment advice.
More information: Yahoo Analyst Estimates | WSJ Ratings
Fact: Key peers in psychedelic/mental health biotech include Compass Pathways (CMPS - psilocybin), GH Research (GHRS), MindMed, Cybin, and others like Tryp Therapeutics or Definium.[MarketBeat] [CB Insights]
| Competitor | Focus Area | Notes |
|---|---|---|
| Compass Pathways (CMPS) | Psilocybin therapy (COMP360) | Direct pipeline overlap in depression |
| GH Research (GHRS) | Psychedelic compounds | Similar mental health focus |
| MindMed | Psychedelic-inspired medicines | Clinical-stage competitor |
| Cybin | Psychedelic therapies | Deuterated compounds |
| Others (e.g., Sage Therapeutics, Axsome) | Broader CNS/mental health | Approved or later-stage products |
Interpretation: Competition is intense in the emerging psychedelic space; differentiation via specific compounds, formulations (e.g., nasal vs. oral), and duration of effect is key.
Uncertainty: Relative positioning could shift dramatically with trial readouts or regulatory decisions; larger pharma (e.g., via acquisitions) may enter or consolidate the space.
More information: MarketBeat Competitors | Seeking Alpha Peers
More information: Company Investor Relations | Yahoo News